Class information for:
Level 1: OMALIZUMAB//ANTI IGE//ANTI IMMUNOGLOBULIN E

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
9018 1128 36.5 81%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
565 13683 MASTOCYTOSIS//MAST CELLS//MAST CELL

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 OMALIZUMAB Author keyword 239 59% 24% 269
2 ANTI IGE Author keyword 67 49% 9% 101
3 ANTI IMMUNOGLOBULIN E Author keyword 30 79% 2% 19
4 FC EPSILON RI Author keyword 27 25% 8% 92
5 HIGH AFFINITY IGE RECEPTOR Author keyword 12 48% 2% 19
6 ANTI IGE ANTIBODY Author keyword 10 61% 1% 11
7 ALLERGOONCOLOGY Author keyword 8 70% 1% 7
8 CD SENS Author keyword 8 70% 1% 7
9 RHUMAB E25 Author keyword 8 100% 0% 5
10 XOLAIR Author keyword 7 57% 1% 8

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 OMALIZUMAB 239 59% 24% 269 Search OMALIZUMAB Search OMALIZUMAB
2 ANTI IGE 67 49% 9% 101 Search ANTI+IGE Search ANTI+IGE
3 ANTI IMMUNOGLOBULIN E 30 79% 2% 19 Search ANTI+IMMUNOGLOBULIN+E Search ANTI+IMMUNOGLOBULIN+E
4 FC EPSILON RI 27 25% 8% 92 Search FC+EPSILON+RI Search FC+EPSILON+RI
5 HIGH AFFINITY IGE RECEPTOR 12 48% 2% 19 Search HIGH+AFFINITY+IGE+RECEPTOR Search HIGH+AFFINITY+IGE+RECEPTOR
6 ANTI IGE ANTIBODY 10 61% 1% 11 Search ANTI+IGE+ANTIBODY Search ANTI+IGE+ANTIBODY
7 ALLERGOONCOLOGY 8 70% 1% 7 Search ALLERGOONCOLOGY Search ALLERGOONCOLOGY
8 CD SENS 8 70% 1% 7 Search CD+SENS Search CD+SENS
9 RHUMAB E25 8 100% 0% 5 Search RHUMAB+E25 Search RHUMAB+E25
10 XOLAIR 7 57% 1% 8 Search XOLAIR Search XOLAIR

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SEVERE ALLERGIC ASTHMA 92 60% 9% 99
2 ANTIIMMUNOGLOBULIN E ANTIBODY 79 85% 4% 41
3 ANTI IGE ANTIBODY 73 44% 11% 124
4 HUMAN IMMUNOGLOBULIN E 60 66% 5% 56
5 SEVERE PERSISTENT ASTHMA 40 37% 8% 88
6 ANTIIMMUNOGLOBULIN E THERAPY 38 62% 3% 39
7 HIGH AFFINITY RECEPTOR 33 20% 13% 150
8 ANTIIMMUNOGLOBULIN E 30 84% 1% 16
9 OMALIZUMAB 29 27% 8% 93
10 FC EPSILON RI 26 10% 22% 249

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
The Use of Anti-IgE Therapy Beyond Allergic Asthma 2015 3 42 43%
IgE in allergy and asthma today 2008 318 100 24%
Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma A Systematic Review 2011 77 22 64%
Targeting IgE in asthma 2012 18 42 90%
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation 2005 189 29 72%
New developments in Fc epsilon RI regulation, function and inhibition 2007 219 161 31%
Omalizumab in Asthma: An Update on Recent Developments 2014 9 74 69%
Anti-IgE Therapy: Clinical Utility and Mechanistic Insights 2015 1 78 63%
Anti-IgE for chronic asthma in adults and children 2006 75 35 69%
Omalizumab for asthma in adults and children 2014 6 78 69%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 MOL BIOLBUNKYO KU 4 75% 0.3% 3
2 ALLERGY ATOPY 2 67% 0.2% 2
3 PEDIAT P DIS ALLERGY 2 67% 0.2% 2
4 SURG MED MOL BIOL CRIT CARE 2 67% 0.2% 2
5 RCMB 2 36% 0.4% 4
6 ALLERGY BUNKYO KU 1 100% 0.2% 2
7 ARBEITSGRP PNEUMOL ALLERGOL MUKOVISZIDOSE 1 100% 0.2% 2
8 FED RECH 17 1 100% 0.2% 2
9 INTERNAL MED P INFECT DIS 1 50% 0.2% 2
10 BIOSCI DEV 1 16% 0.5% 6

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000153848 AUTOANTI IGE//IGG ANTI IGE//ANTI IGE AUTOANTIBODY
2 0.0000132642 INDUCED SPUTUM//SPUTUM CELL COUNTS//SEVERE ASTHMA
3 0.0000126516 CD23//SOLUBLE CD23//LOW AFFINITY IGE RECEPTOR
4 0.0000119954 BASOPHILS//BASOPHIL//HUMAN BASOPHILS
5 0.0000114983 MOL INFLAMMAT SECT//FC EPSILON RI//HUMAN LUNG MAST CELL
6 0.0000113638 BASOPHILIC LEUKEMIA CELL//SECT CHEM IMMUNOL//RBL 2H3 CELLS
7 0.0000074359 STEROID DEPENDENT ASTHMA//STEROID SPARING AGENTS//ALLERGY P CARE
8 0.0000066988 HYBROTEC//ASTER YOMENA//ENERGY TRANSFER PROBE
9 0.0000063990 SUPLATAST TOSILATE//FAMILY COMMUNITY MED PUBL HLTH SCI//IPD 1151T SUPLATAST TOSILATE
10 0.0000059216 ATOPY PATCH TEST//ENVIRONM DERMATOL ALLERGY GSF//PAEDIAT ALLERGY SERV